Top

Published in:

01-03-2016 | Original Communication

Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients

Authors: Antoine Kourilsky, Guillaume Bertrand, Renata Ursu, Jennifer Doridam, Ciprian Barlog, Thierry Faillot, Emmanuel Mandonnet, Catherine Belin, Christine Levy, Antoine F. Carpentier

Published in: Journal of Neurology | Issue 3/2016

Abstract

Glioblastoma patients often require chronic administration of steroids due to peri-tumoral edema. Preliminary studies showed that treatment with Angiotensin-II Receptor Blockers (ARBs) for high blood pressure might be associated with reduced peri-tumoral edema. In this study, we aim to radiologically assess the effect of ARBs on peri-tumoral edema. We conducted a cross-sectional survey on patients with newly diagnosed GBM. Patients treated with ARBs for high blood pressure were paired to non ARB-treated patients based on similar age, tumor location and tumor size. Patients taking steroids at the time of pre-operative Magnetic Resonance Imaging were excluded from the study. In each pair of patients, we compared the volumes of peri-tumoral hyper T2-Fluid Attenuated Inversion Recovery (FLAIR) signal and the Apparent Diffusion Coefficient (ADC) in the same area. Eleven (11) ARB-treated patients were selected and paired to 11 non ARB-treated controls. Volumes of peri-tumoral hyper T2-FLAIR signal were significantly lower in the ARB-treated group than in the non ARB-treated group (p = 0.02). Additionally, peri-tumoral ADCs were also significantly lower in the treated group (p = 0.02), suggesting that the peri-tumoral area in this group had less edematous features. These results suggest that ARBs may reduce the volume of peri-tumoral hyper T2-FLAIR signal by decreasing edema.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Marantidou A, Levy C, Duquesne A, Ursu R, Bailon O, Coman I et al (2010) Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol 100:89–94CrossRefPubMed

Hempen C, Weiss E, Hess CF (2002) Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 10:322–328CrossRefPubMed

Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299CrossRefPubMed

Fogarty DJ, Sánchez-Gómez MV, Matute C (2002) Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 39:304–313CrossRefPubMed

Juillerat-Jeanneret L, Gasc J-M, Corvol P (2004) The renin-angiotensin system in human brain and brain tumors: a function unrelated to blood pressure control? Bull Acad Natl Med 188:639–646 (discussion 647–648) PubMed

Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447CrossRefPubMed

Egami K, Murohara T, Shimada T, Sasaki K-I, Shintani S, Sugaya T et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75CrossRefPubMedPubMedCentral

Imai N, Hashimoto T, Kihara M, Yoshida S, Kawana I, Yazawa T et al (2007) Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 87:189–198CrossRefPubMed

10.

Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 85:1396–1399CrossRefPubMedPubMedCentral

11.

Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679CrossRefPubMedPubMedCentral

12.

Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247–1252CrossRefPubMedPubMedCentral

13.

Ando H, Jezova M, Zhou J, Saavedra JM (2004) Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann N Y Acad Sci 1018:345–350CrossRefPubMed

14.

Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171:852–858CrossRefPubMed

15.

Sano H, Hosokawa K, Kidoya H, Takakura N (2006) Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 26:2673–2680CrossRefPubMed

16.

Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60CrossRefPubMed

17.

Chien D, Kwong KK, Gress DR, Buonanno FS, Buxton RB, Rosen BR (1992) MR diffusion imaging of cerebral infarction in humans. AJNR Am J Neuroradiol 13:1097–1102 (discussion 1103–1105) PubMed

18.

Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM et al (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16:361–371PubMed

19.

Els T, Eis M, Hoehn-Berlage M, Hossmann KA (1995) Diffusion-weighted MR imaging of experimental brain tumors in rats. MAGMA 3:13–20CrossRefPubMed

20.

Tien RD, Felsberg GJ, Friedman H, Brown M, MacFall J (1994) MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677CrossRefPubMed

21.

Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548CrossRefPubMedPubMedCentral

22.

Tom B, Dendorfer A, de Vries R, Saxena PR, Jan Danser AH (2002) Bradykinin potentiation by ACE inhibitors: a matter of metabolism. Br J Pharmacol 137:276–284CrossRefPubMedPubMedCentral

23.

Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy A-L et al (2012) Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol 19:1337–1342CrossRefPubMed

24.

Saavedra JM (2012) Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci 123:567–590CrossRefPubMedPubMedCentral

25.

Fleegal-DeMotta MA, Doghu S, Banks WA (2009) Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J Cereb Blood Flow Metab 29:640–647CrossRefPubMed

26.

Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R et al (2007) Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 27:9032–9042CrossRefPubMed

27.

Li Z, Cao Y, Li L, Liang Y, Tian X, Mo N et al (2014) Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction. Biochem Biophys Res Commun 449:74–80CrossRefPubMed

Title: Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients
Authors: Antoine Kourilsky
Guillaume Bertrand
Renata Ursu
Jennifer Doridam
Ciprian Barlog
Thierry Faillot
Emmanuel Mandonnet
Catherine Belin
Christine Levy
Antoine F. Carpentier
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-015-8016-9

At a glance: The STEP trials

Springer Medicine

Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Motor network structure and function are associated with motor performance in Huntington’s disease

Functional neurological disorders: mechanisms and treatment

Early-onset progressive spastic paraplegia caused by a novel TUBB4A mutation: brain MRI and FDG-PET findings

Two cases of multiple sclerosis manifesting after in vitro fertilization procedures

Association of seizure duration and outcome in refractory status epilepticus

Primary familial brain calcification in a Norwegian family, caused by a novel SLC20A2 gene mutation